New drug MT-304 targets Hard-to-Treat HER2 cancers in early trial

NCT ID NCT07334119

First seen Jan 12, 2026 · Last updated May 04, 2026 · Updated 13 times

Summary

This early-phase study tests a new drug called MT-304, given alone or with another drug (nivolumab), in adults with advanced HER2-expressing solid tumors. The main goals are to check safety and find the best dose. About 60 participants will receive the treatment every two to four weeks until their disease gets worse or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 EXPRESSING SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cabrini Health

    RECRUITING

    Melbourne, Victoria, 3144, Australia

    Contact Phone: •••-•••-••••

    Contact

  • Calvary Mater Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

    Contact

    Contact Phone: •••-•••-••••

  • Cancer Research SA Pty Ltd

    RECRUITING

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-••••

    Contact

  • Icon Cancer Centre South Brisbane

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

    Contact Phone: •••-•••-••••

    Contact

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

    Contact Phone: •••-•••-••••

    Contact

  • Scientia Clinical Research Ltd

    RECRUITING

    Randwick, New South Wales, 2031, Australia

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.